Chilton Capital Management’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $38.1M | Buy |
201,189
+8,130
| +4% | +$1.53M | 1.2% | 29 |
|
|
2026
Q1 | $38.1M | Sell |
193,059
-5,507
| -3% | -$1.06M | 1.33% | 23 |
|
|
2025
Q4 | $36.5M | Sell |
198,566
-3,397
| -2% | -$596K | 1.26% | 25 |
|
|
2025
Q3 | $31M | Buy |
201,963
+3,156
| +2% | +$478K | 1.04% | 30 |
|
|
2025
Q2 | $27.8M | Buy |
198,807
+13,391
| +7% | +$1.88M | 1.01% | 38 |
|
|
2025
Q1 | $27.3M | Buy |
185,416
+4,193
| +2% | +$607K | 1.18% | 31 |
|
|
2024
Q4 | $23.7M | Buy |
181,223
+6,445
| +4% | +$902K | 1% | 34 |
|
|
2024
Q3 | $27.2M | Buy |
174,778
+11,525
| +7% | +$1.86M | 1.13% | 28 |
|
|
2024
Q2 | $25.5M | Sell |
163,253
-2,474
| -1% | -$372K | 1.14% | 27 |
|
|
2024
Q1 | $22.5M | Buy |
165,727
+4,743
| +3% | +$628K | 1.06% | 32 |
|
|
2023
Q4 | $21.7M | Buy |
160,984
+4,803
| +3% | +$624K | 1.1% | 36 |
|
|
2023
Q3 | $21.2M | Buy |
156,181
+2,645
| +2% | +$361K | 1.19% | 29 |
|
|
2023
Q2 | $22M | Sell |
153,536
-924
| -0.6% | -$136K | 1.2% | 31 |
|
|
2023
Q1 | $21.4M | Buy |
154,460
+907
| +0.6% | +$122K | 1.24% | 23 |
|
|
2022
Q4 | $20.8M | Sell |
153,553
-3,762
| -2% | -$472K | 1.3% | 24 |
|
|
2022
Q3 | $17.3M | Buy |
157,315
+452
| +0.3% | +$57.3K | 1.15% | 30 |
|
|
2022
Q2 | $20.7M | Sell |
156,863
-404
| -0.3% | -$53K | 1.26% | 26 |
|
|
2022
Q1 | $20.9M | Sell |
157,267
-1,470
| -0.9% | -$176K | 1.09% | 34 |
|
|
2021
Q4 | $18.5M | Buy |
158,737
+2,289
| +1% | +$269K | 0.94% | 44 |
|
|
2021
Q3 | $18.8M | Buy |
156,448
+4,522
| +3% | +$526K | 1.05% | 39 |
|
|
2021
Q2 | $18.2M | Buy |
151,926
+2,607
| +2% | +$286K | 1.05% | 42 |
|
|
2021
Q1 | $14.8M | Buy |
149,319
+5,809
| +4% | +$584K | 0.99% | 49 |
|
|
2020
Q4 | $14.3M | Buy |
143,510
+1,705
| +1% | +$181K | 1.03% | 45 |
|
|
2020
Q3 | $15.5M | Sell |
141,805
-2,245
| -2% | -$250K | 1.21% | 29 |
|
|
2020
Q2 | $15.2M | Buy |
144,050
+7,217
| +5% | +$745K | 1.3% | 26 |
|
|
2020
Q1 | $12.2M | Sell |
136,833
-3,954
| -3% | -$372K | 1.23% | 29 |
|
|
2019
Q4 | $14M | Sell |
140,787
-1,584
| -1% | -$149K | 1.12% | 30 |
|
|
2019
Q3 | $12.7M | Sell |
142,371
-748
| -0.5% | -$64.9K | 1.05% | 41 |
|
|
2019
Q2 | $11.8M | Buy |
143,119
+4,139
| +3% | +$325K | 1.01% | 46 |
|
|
2019
Q1 | $11.2M | Buy |
138,980
+45
| +0% | +$3.55K | 0.99% | 46 |
|
|
2018
Q4 | $10.6M | Buy |
138,935
+19,960
| +17% | +$1.56M | 1.02% | 40 |
|
|
2018
Q3 | $9.42M | Buy |
118,975
+115,928
| +3,805% | +$8.77M | 0.78% | 62 |
|
|
2018
Q2 | $214K | Buy |
+3,047
| New | +$219K | 0.02% | 205 |
|
Other funds holding AZN
EP
IA
Chilton Capital Management's AZN Position: Q2 2026 in Review
Chilton Capital Management increased its AstraZeneca (AZN) stake by 4.2% in Q2 2026, buying an estimated $1.53M and bringing the position to 201,189 shares worth $38.1M. The position accounts for 1.2% of the portfolio, ranked #29.
Chilton Capital Management first reported a position in AZN in Q2 2018 and has held it in 33 quarters since. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Chilton Capital Management held 201,189 shares of AstraZeneca worth $38.1M as of Q2 2026.
- Chilton Capital Management bought 8,130 AstraZeneca shares in Q2 2026, an estimated $1.53M.
- AstraZeneca made up 1.2% of Chilton Capital Management's portfolio in Q2 2026, its #29 holding.
- Chilton Capital Management first reported a position in AstraZeneca in Q2 2018 and has held it in 33 quarters since.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Chilton Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.